Overview

Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure

Status:
Completed

Trial end date:
2013-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess efficacy and safety of LBH589 - Panobinostat®, a potent HDACi, in patients with advanced STS who experiment disease progression after or during first-line chemotherapy. The rational is based on the observation of activity of deacetylase inhibitor (DACi) in several pre-clinical models of STS including Synovial sarcoma and Ewing sarcoma.

Phase:

Phase 2

Details

Lead Sponsor:

Centre Leon Berard

Treatments:

Panobinostat